2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.10 Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer

P4.11E.10 Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study evaluated the safety and efficacy of combining sintilimab, an immune checkpoint inhibitor, with anlotinib, an anti-angiogenesis agent, in treating patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS mutations. Thirty patients were enrolled at Peking University Shenzhen Hospital from April 2019 to June 2022. Most had stage IV adenocarcinoma and over half had non-G12C KRAS mutations.<br /><br />The study reported an objective response rate (ORR) of 23.3% and a disease control rate (DCR) of 76.7%. The median progression-free survival (PFS) was 7.4 months while the median overall survival (OS) was 15.1 months. Outcomes were similar for both G12C and non-G12C subtypes. Differences in PFS and OS were noted between patients who had and had not received prior anti-angiogenesis therapy, with the latter group experiencing longer survival metrics.<br /><br />Treatment-related adverse events (TRAEs) were noted in 93.3% of participants, with 23.3% experiencing grade 3-4 TRAEs. Common severe toxicities included hypertension, hand-foot syndrome, rash, elevated alanine aminotransferase (ALT) levels, and proteinuria, though no treatment-related deaths occurred. The study suggests that the sintilimab-anlotinib combination is promising for previously treated patients with advanced KRAS-mutant NSCLC due to its manageable toxicities and efficacy.<br /><br />Further research, specifically phase 3 trials, is recommended to confirm these findings and potentially establish this combination as a standard treatment for patients with this specific genetic mutation profile in NSCLC.

Asset Subtitle

Fen Wang

Meta Tag

Speaker Fen Wang

Topic Metastatic NSCLC – Immunotherapy

Keywords

sintilimab

anlotinib

KRAS mutations

non-small cell lung cancer

NSCLC

immune checkpoint inhibitor

anti-angiogenesis

treatment efficacy

treatment safety

Peking University Shenzhen Hospital